DeHeng Hong Kong, together with DeHeng Law Offices (Tianjin) (“DeHeng Tianjin”), advised Dynasty Fine Wines Group Limited (“Dynasty Fine Wines”) (Stock Code: 828) on its placing of new shares under general mandate. DeHeng Tianjin also assisted Dynasty Fine Wines in submitting the overseas listing filing with the China Securities Regulatory Commission.

Recently Guizhou Dongniang Dongcang Liquor Industry Co., Ltd., the execution party of the Guoshuai Guixiandong Project, introduced Guizhou New-Momentum Industry Development Fund (Limited Partnership) as its second largest shareholder. The Fund will further strengthen the development momentum of the project company, and push the project into a new stage toward the target of an RMB 10 billion output.

On March 31, Tianjin Intellectual Property Court held a public hearing of the case in which the defendant surnamed Zhao was accused of infringing on trade secrets. This was the first trade secret infringement case in China where the loss amount was determined by reasonable license fee after the implementation of the Judicial Interpretation on Handling Criminal Cases of Infringing on Intellectual Property (3) jointly issued by the Supreme People's Court and the Supreme People's Procuratorate.

On January 6, 2022, China National Petroleum Corporation (CNPC) announced the bidding result for its first-class external law firms(2022-2024). DeHeng won the bid for the comprehensive service package in Beijing, and specialist service package in the areas of labor law, resources and environment, competition law and anti-monopoly law.

DeHeng is glad to announce that we are once again successfully selected into the law firm database of the Ministry of Commerce of China (MOFCOM) as outside lawyer according to the list of bid winners released by MOFCOM on November 11, 2021. DeHeng won for the third time the bid for "The International Trade and Investment Disputes Category – Legal Affairs regarding International Investment (Domestic)" and for the fourth time "The Trade Remedy and Trade Barrier Response Category – Trade Barrier and Response to Section 337 Actions."

Recently, Hidea Venture Capital, as the lead investor, completed over RMB 100 million investment in Shanghai Aucta Pharmaceuticals Co., Ltd., which will promote the development and growth of the startups specialized in modified drugs active in the Chinese and American markets.